Review
Copyright ©The Author(s) 2022.
World J Exp Med. Jul 20, 2022; 12(4): 53-67
Published online Jul 20, 2022. doi: 10.5493/wjem.v12.i4.53
Table 1 Randomized clinical trials investigating complement inhibitors in the treatment of coronavirus disease 2019
NCT number
Drug
Mechanism of action
Status
Sponsor
NCT04395456AMY-101C3 inhibitorNot yet recruitingAmyndas Pharmaceuticals S.A.
NCT04402060APL-9C3 inhibitorCompletedApellis Pharmaceuticals, Inc.
NCT04346797EculizumabC5 inhibitorRecruitingAssistance Publique- Hôpitaux de Paris
NCT04355494EculizumabC5 inhibitorExpanded access no longer availableAlexion Pharmaceuticals
NCT04288713EculizumabC5 inhibitorExpanded access availableHudson Medical
NCT04351503EculizumabC5 inhibitorRecruitingUniversity Hospital, Basel, Switzerland
NCT04369469RavulizumabC5 inhibitorTerminated (Met futility bar at interim analysis)Alexion Pharmaceuticals
NCT04382755Zilucoplan (RA101495)C5 inhibitorCompletedUniversity Hospital, Ghent
NCT04371367AvdoralimabAnti-C5aRCompletedAssistance Publique Hopitaux De; Marseille &Innate Pharma
NCT04414631Conestat alfaC1 esterase inhibitorsTerminatedUniversity Hospital, Basel, Switzerland & Pharming Technologies B.V.
NCT04530136RuconestC1 esterase inhibitorsRecruitingPharming Technologies B.V.
NCT04333420Vilobelimab (IFX-1)C5aRecruitingInflaRx GmbH
NCT04570397RavulizumabC5 inhibitorRecruitingBrigham and Women's Hospital
NCT04390464RavulizumabC5 inhibitorRecruitingCambridge University Hospitals NHS; Foundation Trust; Frances Hall